147 related articles for article (PubMed ID: 23418593)
1. Elite model for the generation of induced pluripotent cancer cells (iPCs).
Lai J; Kong CM; Mahalingam D; Xie X; Wang X
PLoS One; 2013; 8(2):e56702. PubMed ID: 23418593
[TBL] [Abstract][Full Text] [Related]
2. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells.
Utikal J; Polo JM; Stadtfeld M; Maherali N; Kulalert W; Walsh RM; Khalil A; Rheinwald JG; Hochedlinger K
Nature; 2009 Aug; 460(7259):1145-8. PubMed ID: 19668190
[TBL] [Abstract][Full Text] [Related]
3. Nicotinamide overcomes pluripotency deficits and reprogramming barriers.
Son MJ; Son MY; Seol B; Kim MJ; Yoo CH; Han MK; Cho YS
Stem Cells; 2013 Jun; 31(6):1121-35. PubMed ID: 23526681
[TBL] [Abstract][Full Text] [Related]
4. The role of p53 in limiting somatic cell reprogramming.
Liu Y; Hoya-Arias R; Nimer SD
Cell Res; 2009 Nov; 19(11):1227-8. PubMed ID: 19881523
[No Abstract] [Full Text] [Related]
5. Stem cells: The promises and perils of p53.
Krizhanovsky V; Lowe SW
Nature; 2009 Aug; 460(7259):1085-6. PubMed ID: 19713919
[TBL] [Abstract][Full Text] [Related]
6. Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency.
Menendez S; Camus S; Herreria A; Paramonov I; Morera LB; Collado M; Pekarik V; Maceda I; Edel M; Consiglio A; Sanchez A; Li H; Serrano M; Belmonte JC
Aging Cell; 2012 Feb; 11(1):41-50. PubMed ID: 21981310
[TBL] [Abstract][Full Text] [Related]
7. SOX2 and p53 Expression Control Converges in PI3K/AKT Signaling with Versatile Implications for Stemness and Cancer.
Schaefer T; Steiner R; Lengerke C
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664542
[TBL] [Abstract][Full Text] [Related]
8. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype.
Li Y; Li A; Glas M; Lal B; Ying M; Sang Y; Xia S; Trageser D; Guerrero-Cázares H; Eberhart CG; Quiñones-Hinojosa A; Scheffler B; Laterra J
Proc Natl Acad Sci U S A; 2011 Jun; 108(24):9951-6. PubMed ID: 21628563
[TBL] [Abstract][Full Text] [Related]
9. Genome integrity: linking pluripotency and tumorgenicity.
Deng W; Xu Y
Trends Genet; 2009 Oct; 25(10):425-7. PubMed ID: 19801173
[TBL] [Abstract][Full Text] [Related]
10. miR-34 miRNAs provide a barrier for somatic cell reprogramming.
Choi YJ; Lin CP; Ho JJ; He X; Okada N; Bu P; Zhong Y; Kim SY; Bennett MJ; Chen C; Ozturk A; Hicks GG; Hannon GJ; He L
Nat Cell Biol; 2011 Oct; 13(11):1353-60. PubMed ID: 22020437
[TBL] [Abstract][Full Text] [Related]
11. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells.
Takayama N; Nishimura S; Nakamura S; Shimizu T; Ohnishi R; Endo H; Yamaguchi T; Otsu M; Nishimura K; Nakanishi M; Sawaguchi A; Nagai R; Takahashi K; Yamanaka S; Nakauchi H; Eto K
J Exp Med; 2010 Dec; 207(13):2817-30. PubMed ID: 21098095
[TBL] [Abstract][Full Text] [Related]
12. Reprogramming Methods Do Not Affect Gene Expression Profile of Human Induced Pluripotent Stem Cells.
Trevisan M; Desole G; Costanzi G; Lavezzo E; Palù G; Barzon L
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28117672
[TBL] [Abstract][Full Text] [Related]
13. CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A.
Tu Q; Hao J; Zhou X; Yan L; Dai H; Sun B; Yang D; An S; Lv L; Jiao B; Chen C; Lai R; Shi P; Zhao X
Oncogene; 2018 Jan; 37(1):128-138. PubMed ID: 28892048
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional analysis of pluripotency reveals the Hippo pathway as a barrier to reprogramming.
Qin H; Blaschke K; Wei G; Ohi Y; Blouin L; Qi Z; Yu J; Yeh RF; Hebrok M; Ramalho-Santos M
Hum Mol Genet; 2012 May; 21(9):2054-67. PubMed ID: 22286172
[TBL] [Abstract][Full Text] [Related]
15. Incomplete cellular reprogramming of colorectal cancer cells elicits an epithelial/mesenchymal hybrid phenotype.
Hiew MSY; Cheng HP; Huang CJ; Chong KY; Cheong SK; Choo KB; Kamarul T
J Biomed Sci; 2018 Jul; 25(1):57. PubMed ID: 30025541
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors.
Ohashi S; Natsuizaka M; Wong GS; Michaylira CZ; Grugan KD; Stairs DB; Kalabis J; Vega ME; Kalman RA; Nakagawa M; Klein-Szanto AJ; Herlyn M; Diehl JA; Rustgi AK; Nakagawa H
Cancer Res; 2010 May; 70(10):4174-84. PubMed ID: 20424117
[TBL] [Abstract][Full Text] [Related]
17. Linking incomplete reprogramming to the improved pluripotency of murine embryonal carcinoma cell-derived pluripotent stem cells.
Chang G; Miao YL; Zhang Y; Liu S; Kou Z; Ding J; Chen DY; Sun QY; Gao S
PLoS One; 2010 Apr; 5(4):e10320. PubMed ID: 20436676
[TBL] [Abstract][Full Text] [Related]
18. A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma.
De Vito C; Riggi N; Cornaz S; Suvà ML; Baumer K; Provero P; Stamenkovic I
Cancer Cell; 2012 Jun; 21(6):807-21. PubMed ID: 22698405
[TBL] [Abstract][Full Text] [Related]
19. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
20. p53 switches off pluripotency on differentiation.
Lin T; Lin Y
Stem Cell Res Ther; 2017 Feb; 8(1):44. PubMed ID: 28241890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
